


- 33 -

CLAIMS

1. A compound according to formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, isomer or mixture thereof,



Formula I

5 wherein

R_1 and R_2 are independently selected from the group consisting of hydrogen, methyl and ethyl; and Alk is C_{1-4} alkylene.




2. The compound according to claim 1, wherein both R_1 and R_2 are methyl.

10

3. The compound according to any one of claims 1 or 2, wherein Alk is a C_1 or C_2 alkylene.

4. The compound according to any one of the previous claims, wherein the compound is selected from the group consisting of:

- 34 -



- 5 5. A pharmaceutical composition comprising the compound according to any one of the previous claims, and one or more pharmaceutically acceptable carriers.
6. The compound according to any of claims 1 to 4, for use as a medicament.

- 35 -

7. The compound for use according to claim 6, for use in inhibiting neovascularization.
8. The compound for use according to claim 6, for use in the treatment and/or prevention of cancer.
- 5
9. The compound for use according to claim 6, for use in the treatment and/or prevention of an ophthalmic disorder.
- 10
10. The compound for use according to claim 9, wherein said ophthalmic disorder is selected from the group consisting of wet age-related macular degeneration, retinal detachment, posterior uveitis, corneal neovascularization, iris neovascularization, diabetic macular edema, and diabetic retinopathy.
- 15
11. The compound for use according to claim 9 or 10, wherein the treatment and/or prevention comprises administration of the compound by intravitreal injection.
- 20
12. The compound for use according to any one of claims 7 to 10, wherein the inhibition, treatment or prevention further comprises administering a compound that binds to and inhibits the activity of vascular endothelial growth factor (VEGF) or a VEGF receptor.
- 25
13. A combination comprising the compound according to any one of claims 1 to 4; and a compound that binds to and inhibits the activity of vascular endothelial growth factor (VEGF) or a VEGF receptor.
14. The combination of claim 13, for the use as defined in any one of claims 6 to 11.
15. A method for inhibiting neovascularization in a subject in need thereof, the method comprising administering the compound of any one of claims 1 to 4 to the subject.